{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eye+Mask&page=2",
    "query": {
      "intervention": "Eye Mask",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eye+Mask&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T09:23:49.588Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04704921",
      "title": "Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "AMD",
        "nAMD",
        "Wet Age-related Macular Degeneration",
        "wAMD",
        "Wet AMD",
        "CNV",
        "Neovascular AMD",
        "Neovascular Age-related Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "ABBV-RGX-314",
          "type": "GENETIC"
        },
        {
          "name": "Ranibizumab (LUCENTIS®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "BIOLOGICAL"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 671,
      "start_date": "2020-12-29",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-09-07T09:23:49.588Z",
      "location_count": 89,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04704921"
    },
    {
      "nct_id": "NCT05165290",
      "title": "Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Elevated Intraocular Pressure"
      ],
      "interventions": [
        {
          "name": "Latanoprost ophthalmic solution, 0.005%",
          "type": "DRUG"
        },
        {
          "name": "TC-002 latanoprost ophthalmic solution, 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TearClear Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2021-11-29",
      "completion_date": "2022-09",
      "has_results": false,
      "last_update_posted_date": "2022-05-25",
      "last_synced_at": "2026-09-07T09:23:49.588Z",
      "location_count": 20,
      "location_summary": "Garden Grove, California • Glendale, California • Mission Hills, California + 16 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05165290"
    },
    {
      "nct_id": "NCT06307613",
      "title": "A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Efgartigimod PH20 SC",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo PH20 SC",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2024-03-27",
      "completion_date": "2026-02-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-09-07T09:23:49.588Z",
      "location_count": 16,
      "location_summary": "Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06307613"
    },
    {
      "nct_id": "NCT01382810",
      "title": "Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye Syndromes"
      ],
      "interventions": [
        {
          "name": "Altaire Gel forming solution",
          "type": "DRUG"
        },
        {
          "name": "Refresh Tears",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innovative Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2011-03",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2012-06-14",
      "last_synced_at": "2026-09-07T09:23:49.588Z",
      "location_count": 2,
      "location_summary": "Lake Villa, Illinois • Warwick, Rhode Island",
      "locations": [
        {
          "city": "Lake Villa",
          "state": "Illinois"
        },
        {
          "city": "Warwick",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01382810"
    },
    {
      "nct_id": "NCT06864988",
      "title": "4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Neovascularization Secondary to Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "4D-150 IVT (3E10 vg/eye)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "4D Molecular Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 480,
      "start_date": "2025-03-03",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-09-07T09:23:49.588Z",
      "location_count": 91,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 79 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06864988"
    },
    {
      "nct_id": "NCT06100939",
      "title": "Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratoconus"
      ],
      "interventions": [
        {
          "name": "Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo and sham treatment",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Epion Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "8 Years to 45 Years"
      },
      "enrollment_count": 396,
      "start_date": "2023-10-30",
      "completion_date": "2026-06-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-09-07T09:23:49.588Z",
      "location_count": 13,
      "location_summary": "Rowland Heights, California • San Francisco, California • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Rowland Heights",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Hoffman Estates",
          "state": "Illinois"
        },
        {
          "city": "Brookline",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06100939"
    },
    {
      "nct_id": "NCT04785690",
      "title": "CURESIGHT BINOCULAR AMBLYOPIA TREATMENT STUDY",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Amblyopia"
      ],
      "interventions": [
        {
          "name": "CureSight",
          "type": "DEVICE"
        },
        {
          "name": "Patching",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "NovaSight",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "4 Years to 8 Years"
      },
      "enrollment_count": 23,
      "start_date": "2021-03-31",
      "completion_date": "2023-05-01",
      "has_results": false,
      "last_update_posted_date": "2023-08-08",
      "last_synced_at": "2026-09-07T09:23:49.588Z",
      "location_count": 1,
      "location_summary": "Virginia Beach, Virginia",
      "locations": [
        {
          "city": "Virginia Beach",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04785690"
    },
    {
      "nct_id": "NCT06090370",
      "title": "Reducing Silica Exposure Among Brick Kiln Workers in Nepal",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Silicosis"
      ],
      "interventions": [
        {
          "name": "N95 Respirator",
          "type": "DEVICE"
        },
        {
          "name": "Protective Eyewear",
          "type": "DEVICE"
        },
        {
          "name": "Baseline Survey",
          "type": "OTHER"
        },
        {
          "name": "Design of Workshop",
          "type": "OTHER"
        },
        {
          "name": "Training Workshop Pilot",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2024-01-24",
      "completion_date": "2024-06-20",
      "has_results": false,
      "last_update_posted_date": "2024-06-24",
      "last_synced_at": "2026-09-07T09:23:49.588Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Durham, North Carolina",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06090370"
    },
    {
      "nct_id": "NCT04784390",
      "title": "Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Amblyopia"
      ],
      "interventions": [
        {
          "name": "Binocular video games",
          "type": "DEVICE"
        },
        {
          "name": "Patching of the sound eye",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "4 Years to 12 Years"
      },
      "enrollment_count": 27,
      "start_date": "2021-06-30",
      "completion_date": "2022-08-03",
      "has_results": false,
      "last_update_posted_date": "2023-05-23",
      "last_synced_at": "2026-09-07T09:23:49.588Z",
      "location_count": 5,
      "location_summary": "Gainesville, Florida • Maitland, Florida • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Frederick",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04784390"
    },
    {
      "nct_id": "NCT01239069",
      "title": "Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "DE-110 ophthalmic suspension high dose",
          "type": "DRUG"
        },
        {
          "name": "DE-110 ophthalmic suspension low dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2010-11",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2014-05-21",
      "last_synced_at": "2026-09-07T09:23:49.588Z",
      "location_count": 14,
      "location_summary": "Inglewood, California • Newport Beach, California • Petaluma, California + 11 more",
      "locations": [
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Bloomfield",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01239069"
    }
  ]
}